. Author manuscript; available in PMC: 2012 Jun 25.

Published in final edited form as: Gene Ther. 2010 Aug 12;18(1):53–61. doi: 10.1038/gt.2010.111

Table 3. Mean (a) dark-adapted b-wave amplitude (μV) at 0 log cdSm⁻² and (b) light-adapted 33Hz flicker results for all dogs pre- and post-injection, with P-values comparing amplitude of response for first and second treated eyes.

Eye	Pre- injection	2 months	4 months	9–12 months	20–24 months	P-value (pre vs 4months)	P-value (2months vs 4months)	P-value (9-12months vs 20–24months)	P-value (4months vs 20–24months)
(a)
First (a)	0	25	38	36	27	<0.001^*	0.122	0.633	0.235
Second (b)	0	30	32	30	25	<0.001^*	0.573	0.364	0.348
P-value (1st vs 2nd)		0.748	0.722	0.814	0.887
(b)
First (a)	0	4.6	5.8	5.9	3.0	<0.001^*	0.214	0.519	0.10
Second (b)	0	4.5	4.4	4.0	1.9	<0.001^*	0.322	0.157	0.041
P-value (1st vs 2nd)		0.954	0.474	0.303	0.350

Significant difference.

Table 3. Mean (a) dark-adapted b-wave amplitude (μV) at 0 log cdSm−2 and (b) light-adapted 33Hz flicker results for all dogs pre- and post-injection, with P-values comparing amplitude of response for first and second treated eyes.